Mei Ri Jing Ji Xin Wen·2026-02-26 08:37Core Viewpoint - The company, CanSino (688185.SH), reported a significant turnaround in its financial performance for the fiscal year 2025, achieving a total revenue of 1.068 billion yuan, marking a year-on-year growth of 26.18% and a net profit attributable to shareholders of 27.87 million yuan, compared to a loss of 379 million yuan in the previous year [2]. Financial Performance - Total revenue for 2025 reached 1.068 billion yuan, reflecting a 26.18% increase year-on-year [2]. - The net profit attributable to shareholders was 27.87 million yuan, a significant recovery from a loss of 379 million yuan in the same period last year [2]. Product Performance - The revenue from the company's first quadrivalent meningococcal vaccine, Manhaixin®, continued to grow steadily during the reporting period [2]. Research and Development - The company has accelerated its R&D projects and international collaborations, which have contributed to its financial performance [2]. - CanSino received government special subsidies and international research funding, which were recognized as non-recurring gains during the reporting period [2].